340B Drug Pricing Program
The Centers for Medicare & Medicaid Services (CMS) should withdraw its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program, AHA yesterday told the agency in comments on its outpatient prospective payment system proposed rule for calendar year 2018.
Reps. David McKinley (R-WV) and Mike Thompson (D-CA) are collecting signatures for a Dear Colleague letter urging the CMS to rescind its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program.
The Centers for Medicare & Medicaid Services should withdraw its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program, AHA today told the agency in comments on its outpatient prospective payment system proposed rule for calendar year 2018. “CMS…
Submit Comments to CMS on Proposed Cuts to Medicare Part B Payments for 340B Drugs
The panel that advises the Centers for Medicare & Medicaid Services on hospital outpatient payments sent a clear signal to the agency this week: Don’t shortchange patients’ access to vital pharmaceuticals by cutting the 340B Drug Pricing Program. CMS’s Advisory Panel on Hospital Outpatient…
As urged by the AHA and others, a Centers for Medicare & Medicaid Services advisory panel today recommended that the agency not finalize for 2018 a proposal that would drastically cut Medicare payments for drugs acquired under the 340B Drug Pricing Program. In July, CMS proposed to pay…